drugset

drugset / Trial / NCT00688519

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519 ↗

Phase 3 Completed 336 enrolled Stiefel, a GSK Company GlaxoSmithKline · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.

Timeline

Start: 2008-03
Primary completion: 2008-12
Completion: 2008-12

Publications

Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M; U0267-301 & 302 Study Investigators. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol. 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Calcipotriol	Small molecule	0.005 %	Topical

Indications